 "pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing")
Favipiravir brand FabiFlu from Glenmark has catapulted to capture the number one slot in the domestic pharma market in April – from 169th in February.
With sales of Rs 352 crore in April, this brand alone accounted for over 2 per cent of the total domestic pharma market sales of Rs 15,662 crore.
Glenmark said that according to data from market research firm AIOCD AWACS, FabiFlu clocked sales of Rs 351.9 crore in April, a more than seven-fold jump from March.
The huge jump in FabiFlu sales happened owing to a surge in Covid cases during the
With sales of Rs 352 crore in April, this brand alone accounted for over 2 per cent of the total domestic pharma market sales of Rs 15,662 crore.
Glenmark said that according to data from market research firm AIOCD AWACS, FabiFlu clocked sales of Rs 351.9 crore in April, a more than seven-fold jump from March.
The huge jump in FabiFlu sales happened owing to a surge in Covid cases during the
